3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Myeloid
2
Conditions
Myeloproliferative Disorders
3
Primary Myelofibrosis
2
Leukemia, Neutrophilic, Chronic
1
Interventions
fludarabine phosphate
31
Cyclophosphamide
27
Mycophenolic Acid
22
Whole-Body Irradiation
21
Tacrolimus
21
ruxolitinib
19
Peripheral Blood Stem Cell Transplantation
19
Busulfan
19
Antilymphocyte Serum
16
fludarabine
14
Melphalan
12
Methotrexate
11
Cyclosporine
10
thymoglobulin
9
Cord Blood Stem Cell Transplantation
7
Sirolimus
6
Radiotherapy
6
Etoposide
6
Azacitidine
6
Stem Cell Transplantation
5
Granulocyte Colony-Stimulating Factor
5
Cyclosporins
4
pomalidomide
3
parsaclisib
3
Surveys and Questionnaires
3
Rituximab
3
Prednisone
3
Filgrastim
3
Cytarabine
3
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Primary Myelofibrosis
×
fedratinib
×
Clear all
NCT03952039
2025-08-28
FREEDOM2
Celgene
Phase 3
Completed
202 enrolled
23 charts
NCT03755518
2024-12-12
FREEDOM
Celgene
Phase 3
Terminated
38 enrolled
23 charts